TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07172360: A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 420 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07172360 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07172360 Rescue Dossier →